RESUMEN
Skin serves as a drug administration route, and skin permeability of chemicals is of significant interest in the pharmaceutical and cosmetic industries. An aggregated conformal prediction (ACP) framework was used to build models for predicting the permeation rate (log Kp) of chemical compounds through human skin. The conformal prediction method gives as an output the prediction range at a given level of confidence for each compound, which enables the user to make a more informed decision when, for example, suggesting the next compound to prepare. Predictive models were built using both the random forest and the support vector machine methods and were based on experimentally derived permeability data on 211 diverse compounds. The derived models were of similar predictive quality as compared to earlier published models but have the extra advantage of not only presenting a single predicted value for each compound but also a reliable, individually assigned prediction range. The models use calculated descriptors and can quickly predict the skin permeation rate of new compounds.
Asunto(s)
Piel/metabolismo , Humanos , Modelos Teóricos , Conformación Molecular , Absorción Cutánea/fisiología , Máquina de Vectores de SoporteRESUMEN
Virtual screening has the potential to accelerate and reduce costs of probe development and drug discovery. To develop and benchmark virtual screening methods, validation data sets are commonly used. Over the years, such data sets have been constructed to overcome the problems of analogue bias and artificial enrichment. With the rapid growth of public domain databases containing high-throughput screening data, such as the PubChem BioAssay database, there is an increased possibility to use such data for validation. In this study, we identify PubChem data sets suitable for validation of both structure- and ligand-based virtual screening methods. To achieve this, high-throughput screening data for which a crystal structure of the bioassay target was available in the PDB were identified. Thereafter, the data sets were inspected to identify structures and data suitable for use in validation studies. In this work, we present seven data sets (MMP13, DUSP3, PTPN22, EPHX2, CTDSP1, MAPK10, and CDK5) compiled using this method. In the seven data sets, the number of active compounds varies between 19 and 369 and the number of inactive compounds between 59 405 and 337 634. This gives a higher ratio of the number of inactive to active compounds than what is found in most benchmark data sets. We have also evaluated the screening performance using docking and 3D shape similarity with default settings. To characterize the data sets, we used physicochemical similarity and 2D fingerprint searches. We envision that these data sets can be a useful complement to current data sets used for method evaluation.
Asunto(s)
Benchmarking/métodos , Ensayos Analíticos de Alto Rendimiento/métodos , Relación Estructura-Actividad , Algoritmos , Simulación por Computador , Bases de Datos de Compuestos Químicos , Ligandos , Conformación Molecular , Reproducibilidad de los Resultados , Interfaz Usuario-ComputadorRESUMEN
The antimalarial compound fosmidomycin targets DXR, the enzyme that catalyzes the first committed step in the MEP pathway, producing the essential isoprenoid precursors, isopentenyl diphosphate and dimethylallyl diphosphate. The MEP pathway is used by a number of pathogens, including Mycobacterium tuberculosis and apicomplexan parasites, and differs from the classical mevalonate pathway that is essential in humans. Using a structure-based approach, we designed a number of analogues of fosmidomycin, including a series that are substituted in both the Cα and the hydroxamate positions. The latter proved to be a stable framework for the design of inhibitors that extend from the polar and cramped (and so not easily druggable) substrate-binding site and can, for the first time, bridge the substrate and cofactor binding sites. A number of these compounds are more potent than fosmidomycin in terms of killing Plasmodium falciparum in an in vitro assay; the best has an IC50 of 40 nM.
Asunto(s)
Isomerasas Aldosa-Cetosa/antagonistas & inhibidores , Antimaláricos/síntesis química , Fosfomicina/análogos & derivados , Isomerasas Aldosa-Cetosa/química , Antimaláricos/química , Antimaláricos/farmacología , Cristalografía por Rayos X , Escherichia coli/enzimología , Fosfomicina/síntesis química , Fosfomicina/química , Fosfomicina/farmacología , Ácidos Hidroxámicos/síntesis química , Ácidos Hidroxámicos/química , Ácidos Hidroxámicos/farmacología , Concentración 50 Inhibidora , Modelos Moleculares , Mycobacterium tuberculosis/enzimología , Plasmodium falciparum/efectos de los fármacos , Plasmodium falciparum/enzimología , Unión Proteica , Conformación Proteica , Relación Estructura-ActividadRESUMEN
Mycobacterium tuberculosis glutamine synthetase (MtGS) is a promising target for antituberculosis drug discovery. In a recent high-throughput screening study we identified several classes of MtGS inhibitors targeting the ATP-binding site. We now explore one of these classes, the 2-tert-butyl-4,5-diarylimidazoles, and present the design, synthesis, and X-ray crystallographic studies leading to the identification of MtGS inhibitors with submicromolar IC(50) values and promising antituberculosis MIC values.
Asunto(s)
Antituberculosos/síntesis química , Glutamato-Amoníaco Ligasa/antagonistas & inhibidores , Imidazoles/síntesis química , Mycobacterium tuberculosis/efectos de los fármacos , Adenosina Trifosfato/metabolismo , Antituberculosos/química , Antituberculosos/farmacología , Sitios de Unión , Cristalografía por Rayos X , Imidazoles/química , Imidazoles/farmacología , Pruebas de Sensibilidad Microbiana , Modelos Moleculares , Estructura Molecular , Mycobacterium tuberculosis/enzimología , Relación Estructura-ActividadRESUMEN
Two series of FR900098/fosmidomycin analogs were synthesized and evaluated for MtDXR inhibition and Mycobacterium tuberculosis whole-cell activity. The design rationale of these compounds involved the exchange of either the phosphonic acid or the hydroxamic acid part for alternative acidic and metal-coordinating functionalities. The best inhibitors provided IC(50) values in the micromolar range, with a best value of 41 µM.
Asunto(s)
Isomerasas Aldosa-Cetosa/antagonistas & inhibidores , Antituberculosos/farmacología , Inhibidores Enzimáticos/farmacología , Fosfomicina/análogos & derivados , Complejos Multienzimáticos/antagonistas & inhibidores , Mycobacterium tuberculosis/efectos de los fármacos , Oxidorreductasas/antagonistas & inhibidores , Isomerasas Aldosa-Cetosa/metabolismo , Antituberculosos/síntesis química , Antituberculosos/química , Cristalografía por Rayos X , Relación Dosis-Respuesta a Droga , Inhibidores Enzimáticos/síntesis química , Inhibidores Enzimáticos/química , Fosfomicina/síntesis química , Fosfomicina/química , Fosfomicina/farmacología , Ácidos Hidroxámicos/química , Pruebas de Sensibilidad Microbiana , Modelos Moleculares , Estructura Molecular , Complejos Multienzimáticos/metabolismo , Mycobacterium tuberculosis/enzimología , Organofosfonatos/química , Oxidorreductasas/metabolismo , Estereoisomerismo , Relación Estructura-ActividadRESUMEN
The natural antibiotic fosmidomycin acts via inhibition of 1-deoxy-d-xylulose 5-phosphate reductoisomerase (DXR), an essential enzyme in the non-mevalonate pathway of isoprenoid biosynthesis. Fosmidomycin is active on Mycobacterium tuberculosis DXR (MtDXR), but it lacks antibacterial activity probably because of poor uptake. α-Aryl substituted fosmidomycin analogues have more favorable physicochemical properties and are also more active in inhibiting malaria parasite growth. We have solved crystal structures of MtDXR in complex with 3,4-dichlorophenyl substituted fosmidomycin analogues; these show important differences compared to our previously described forsmidomycin-DXR complex. Our best inhibitor has an IC(50) = 0.15 µM on MtDXR but still lacked activity in a mycobacterial growth assay (MIC > 32 µg/mL). The combined results, however, provide insights into how DXR accommodates the new inhibitors and serve as an excellent starting point for the design of other novel and more potent inhibitors, particularly against pathogens where uptake is less of a problem, such as the malaria parasite.